Skip to Content Skip to Search

Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GSK. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

  • FY 2022-2026 Income statement and product revenue figures are as at 06/09/2022
Income Statement

 

£m (unless stated) 2022 2023 2024 2025 2026 2022-2026 n=
Turnover - Specialty ex pandemic solutions 8,718 9,909 10,965 11,953 12,794 14
Turnover - General Medicines 9,805 9,765 9,664 9,560 9,463 14
Turnover - Vaccines ex pandemic solutions 7,668 8,659 9,607 10,541 11,287 14
Turnover - GSK excluding pandemic solutions 26,191 28,334 30,236 32,054 33,544 14
Turnover - pandemic solutions 1,899 155 98 67 52 14
Turnover - GSK 28,090 28,489 30,334 32,120 33,596 14
Cost of sales (8,403) (7,777) (8,131) (8,534) (8,840) 14
Selling, general and administration (7,688) (7,953) (8,259) (8,531) (8,727) 14
Research and Development (4,934) (5,186) (5,431) (5,668) (5,836) 14
Royalty income 643 711 430 464 489 14
Operating profit 7,708 8,285 8,942 9,852 10,682 14
Net finance costs (763) (691) (651) (618) (590) 14
Associates 3 4 4 4 4 14
Profit before tax 6,948 7,598 8,295 9,237 10,097 14
Taxation (1,117) (1,257) (1,384) (1,547) (1,693) 14
Tax Rate 16.1% 16.5% 16.7% 16.7% 16.8% 14
Profit after tax  5,831 6,340 6,911 7,691 8,403 14
Minority interests (611) (648) (690) (728) (757) 14
Profit attributable to shareholders 5,220 5,693 6,221 6,963 7,646 14
WANS (m) 4,025 4,046 4,062 4,078 4,089 14
Earnings per share (p) 129.7 140.7 153.2 170.8 187.0 14
Dividend per share (p) 58.5 56.8 59.8 63.1 66.1 13
Free Cash Flow 3,297 4,446 5,185 5,974 6,469 10
Net Debt (14,281) (11,550) (8,642) (3,941) (1,307) 12
             
USD / GBP 1.25 1.22 1.22 1.22 1.22 14
EUR / GBP 1.18 1.17 1.18 1.18 1.18 14
JPY / GBP 160 163 163 163 163 11

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research.

Specialty medicines

 

Turnover £m 2022 2023 2024 2025 2026 2022-2026 n=
             
Tivicay 1,329 1,253 1,157 1,070 989 14
Triumeq 1,750 1,573 1,391 1,254 1,123 14
Juluca 606 660 692 717 737 14
Dovato 1,268 1,624 1,890 2,075 2,227 14
Dolutegravir based regimens 4,953 5,111 5,131 5,117 5,077 14
Cabenuva 303 542 791 1,041 1,244 14
Apretude 46 152 282 412 514 14
Cabotegravir +/- rilpivirine 349 693 1,073 1,453 1,758 14
Rukobia 87 125 154 176 197 14
Other HIV 103 89 82 83 94 n/a
HIV 5,492 6,019 6,440 6,829 7,126 14
             
Benlysta 1,142 1,301 1,405 1,424 1,400 14
Nucala 1,406 1,567 1,673 1,743 1,780 14
             
Zejula 479 583 666 752 831 14
Blenrep 131 208 287 358 424 14
Jemperli 26 60 95 129 158 14
             
momelotinib - 36 99 175 255 13
             
daprodustat 14 105 204 297 367 13
             
Specialty Medicines ex pandemic solutions 8,718 9,909 10,965 11,953 12,794 14
             
Xevudy 1,884 144 67 46 37 14
             
Specialty Medicines 10,602 10,053 11,032 11,999 12,831 14

 

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research.

Vaccines

 

Turnover £m 2022 2023 2024 2025 2026 2022-2026 n=
Bexsero 735 792 819 840 858 14
Menveo 311 330 337 342 345 14
Other Meningitis 30 32 32 32 32 8
Meningitis 1,076 1,154 1,188 1,214 1,235 14
Fluarix/Flulaval 712 745 763 782 801 14
Shingrix 2,799 3,416 3,961 4,354 4,663 14
Boostrix 582 603 612 622 631 14
Cervarix 112 114 114 115 116 13
Hepatitis 564 618 644 666 682 14
Infanrix, Pediarix 577 584 583 583 584 14
Rotarix 553 574 585 596 606 14
Synflorix 332 334 329 321 314 14
Established Vaccines 3,080 3,192 3,224 3,262 3,292 14
RSV OA - 136 409 787 1,037 14
Vaccines ex pandemic solutions 7,668 8,659 9,607 10,541 11,287 14
Pandemic solutions 15 12 31 21 15 14
Vaccines 7,683 8,671 9,637 10,561 11,302 14

 

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research.

General medicines

 

Turnover £m 2022 2023 2024 2025 2026 2022-2026 n=
Anoro 468 488 492 493 494 14
Arnuity 58 61 62 63 64 14
Avamys/Veramyst 302 274 251 235 222 13
Flixotide/Flovent 484 444 419 398 378 14
Incruse 212 219 224 227 232 14
Relvar/Breo 1,123 1,113 1,100 1,085 1,072 14
Seretide/Advair 1,130 1,013 913 829 759 14
Trelegy 1,743 2,082 2,324 2,515 2,677 14
Ventolin 715 676 642 612 584 14
Respiratory 6,360 6,484 6,533 6,554 6,571 14
Other General Medicines 3,445 3,281 3,132 3,006 2,892 14
             
General Medicines 9,805 9,765 9,664 9,560 9,463 14

 

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research.

Back to top